Potassium Supplementation to Reduce Blood Pressure

Overview

The aim of this study is to conduct a definitive trial to assess the efficacy of consuming 1L/day of water rich in potassium to reduce blood pressure in mild to moderately hypertensive adults. The objective is to assess the potential effect of the intervention on reducing systolic blood pressure. This study will comprise of a 4 week, double-blind, parallel randomised controlled trial. Participants will be adults with systolic blood pressure measurements of 130mmHg or greater. The intervention comprises advice to consume bottled water rich in potassium. The comparator will be regular bottled mineral water.This study will recruit 40 people with elevated systolic blood pressure (≥130mmHg) who are not regularly taking antihypertensive medication.

Full Title of Study: “Testing the Potential Effect of a Potassium-rich Water Intervention on Blood Pressure in Mild to Moderately Hypertensive Adults: a Double-blind Randomised Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: March 1, 2023

Interventions

  • Dietary Supplement: High potassium water
    • High potassium water Potassium 6.2 mg/100ml
  • Dietary Supplement: Control low potassium water
    • Control water Potassium 0.2 mg/100ml

Arms, Groups and Cohorts

  • Experimental: High potassium water
    • All participants will be provided with bottled water for the duration of the 4 week intervention to consume 1L/day. The intervention group will receive high potassium water. Participants will be instructed to consume 1 bottle (500 mL) within 2 hours after waking up and 1 bottle (500 mL) within 2 hours before going to bed (total 1L/day). Participants will continue with the same diet and exercise patterns in their daily life similar to before participating in the study, for the whole length of the intervention.
  • Placebo Comparator: Low potassium control water
    • All participants will be provided with bottled water for the duration of the 4 week intervention to consume 1L/day. The control group will receive regular bottled mineral water. Participants will be instructed to consume 1 bottle (500 mL) within 2 hours after waking up and 1 bottle (500 mL) within 2 hours before going to bed (total 1L/day). Participants will continue with the same diet and exercise patterns in their daily life similar to before participating in the study, for the whole length of the intervention.

Clinical Trial Outcome Measures

Primary Measures

  • Seated home measured systolic blood pressure mm/Hg
    • Time Frame: Blood pressure will be taken at three time points through out the 4 weeks.
    • Blood pressure will me monitored by the participant at home, after detailed instruction are provided by trained researchers over Zoom. Measurements will be taken in duplicate, in the morning and again in the evening (4 times a day total) and the average values will be taken.

Secondary Measures

  • Seated home measured diastolic blood pressure
    • Time Frame: Blood pressure will be taken at three time points through out the 4 weeks
    • Blood pressure will me monitored by the participant at home, after detailed instruction are provided by trained researchers over Zoom. Measurements will be taken in duplicate, in the morning and again in the evening (4 times a day total) and the average values will be taken.
  • Qualitative semi-structured, part open ended survey of acceptability of trial and reported barriers
    • Time Frame: This survey will be administered on the final visit at week 4 of the trial.
    • This survey will be designed by the researchers understand the participant experience of the intervention, in order to optimise any future study expansion. This will include things that worked well and those that did not work as well, during the trial (consumption of the water, convenience, appropriateness of outcome measures, burden on daily activities and lifestyle, etc.)

Participating in This Clinical Trial

Inclusion Criteria

  • Willing and able to provide informed consent – Between 20 to 64 years old – English speaking – Adults who are not receiving antihypertensive pharmacological treatment – Recent (within 6 months) and latest systolic blood pressure measurement ≥130mmHg and/or diastolic ≥85 mmHg – Have access to internet and equipment for video calling – Able to post samples and equipment to OxBCNH – Physically able to take own body measurements and blood pressure Exclusion Criteria:

  • Participation in another research study – Unable to read and understand the instructions provided in English – Unable to comply with experimental procedures or not follow testing safety guidelines – People with cardiovascular conditions: heart attack or stroke within the last 3 months, heart failure of grade II New York Heart Association and more severe, or prolonged QT syndrome, angina, arrhythmia or atrial fibrillation. – Uncontrolled type 2 diabetes (HbA1c> 9%) – Type 2 diabetes controlled using exogenous insulin – Previous or current diagnosis of diabetes complications such as nephropathy, retinopathy and neuropathy. – People with type 1 diabetes – Currently on any medication that may lead to hyperkalemia or fluid retention – Currently being assessed for diagnosis of hypertension (not receiving treatment for high blood pressure) – Already on clinician/HCP supervised diet or restricted diet – They are planning on going away from home (holiday or other) during the 4 week intervention period and will not be able to take water during this time. – Currently prescribed antihypertensive medications, or have been in the last 6 weeks – Chronic kidney disease stage 1 (G1A2 or G1A3), 2 (G2A2 or G2A3), 3a, 3b, 4 or 5 based on UKKA (we will ask whether participants have been diagnosed with kidney disease by a clinician based on this criteria) – They are planning to go on a diet or begin taking supplements containing potassium during the intervention – Pregnant women (including women suspected of being pregnant) and breast-feeding woman.

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 64 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Oxford Brookes University
  • Collaborator
    • Suntory Beverage & Food Limited
  • Provider of Information About this Clinical Study
    • Principal Investigator: Shelly Coe, Senior Lecturer in Nutrition – Oxford Brookes University
  • Overall Contact(s)
    • Shelly Coe, PhD, 07531435736, scoe@brookes.ac.uk

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.